AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9401313
Drug: Substitution therapy
RxNorm normalized name: hydroxypropyl cellulose, low substituted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substitution therapy (replacing one antidepressant with another)
Trial: 9401313
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (adding a second antidepressant to the first)
Trial: 3900456
Drug: TMS-19-Q.GC tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMS-19-Q.GC tablet (TMS)
Trial: 3900457
Drug: Josamycin tablet
RxNorm normalized name: josamycin
DrugBank: Josamycin (DB01321)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Josamycin tablet (JM)
Trial: 27509600
Drug: Acupuncture method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture method of 'Xingnao Kaiqiao' and oral administration of nifedipine (Control group)
Trial: 22669570
Drug: Ridaforolimus 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ridaforolimus 40 mg in fasted state
Trial: 22669570
Drug: Ridaforolimus 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ridaforolimus 40 mg with light breakfast
Trial: 22669570
Drug: Ridaforolimus 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ridaforolimus 40 mg with high-fat breakfast
Trial: 16274475
Drug: Lactobacillus reuteri
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus reuteri (108 Colony Forming Units daily for 80 days)
Trial: 6461999
Drug: d‐tubocurarine (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d‐tubocurarine (0.05 mg/kg)
Trial: 6461999
Drug: alcuronium (0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alcuronium (0.03 mg/kg)
Trial: 6461999
Drug: pancuronium (0.008
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pancuronium (0.008 mg/kg)
Trial: 23769246
Drug: Ketorolac 1
RxNorm normalized name: ketorolac 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 1 mg/kg
Trial: 23769246
Drug: Ketoprofen 50
RxNorm normalized name: ketoprofen 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen 50 mg + 50 mg tramadol
Trial: 23769246
Drug: Ketoprofen 100
RxNorm normalized name: ketoprofen 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen 100 mg + 100 mg tramadol
Trial: 21208398
Drug: Anthelmintic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthelmintic treatment programme (oral ivermectin and fenbendazole)
Trial: 16718798
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL epinephrine
Trial: 16718798
Drug: 30 mL
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mL epinephrine
Trial: 16718798
Drug: 40 mL
RxNorm normalized name: hydrogen peroxide 40 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mL epinephrine
Trial: 11513170
Drug: Eradication treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eradication treatment (lansoprazole 15 mg b.i.d., amoxicillin 1 g b.i.d., clarithromycin 500 mg b.i.d.)
Trial: 11513170
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (lansoprazole 15 mg b.i.d. and placebo)
Trial: 9278202
Drug: Study group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study group received counseling about their medicines and a pharmaceutical care plan.
Trial: 9278202
Drug: Study group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study group had unintentional changes to medication found during the visit.
Trial: 9278202
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group had unintentional changes to medication found during the visit.
Trial: 8305360
Drug: alpha IFN-2b
RxNorm normalized name: RAD-IFN-2B
DrugBank: Nadofaragene firadenovec (DB17381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha IFN-2b maintenance therapy post-DHBI
Trial: 3524665
Drug: Oral oestradiol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral oestradiol, 2 mg daily plus oestriol, 1 mg daily
Trial: 3524665
Drug: Oral oestradiol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral oestradiol, 2 mg daily
Trial: 30916364
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 1g/kg flaxseeds and 1g/kg fenugreek seeds
Trial: 23080086
Drug: Fibrin glue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrin glue spray applied to the axillary fossa in 40 patients
Trial: 23080086
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment in 40 patients
Trial: 2095345
Drug: Furosemide 40
RxNorm normalized name: furosemide 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide 40 mg alone (F)
Trial: 2095345
Drug: Furosemide 40
RxNorm normalized name: furosemide 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide 40 mg and Triamterene 50 mg (F + T)
Trial: 2095345
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of Furosemide 40 mg and Triamterene 50 mg (FT)
Trial: 30452776
Drug: CSL112 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSL112 2 g (n = 6)
Trial: 30452776
Drug: CSL112 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSL112 6 g (n = 6)
Trial: 30452776
Drug: CSL112 (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSL112 (both doses)
Trial: 28457194
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg ICG administered 3 to 7 hours before imaging
Trial: 28457194
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg ICG administered 5 to 25 hours before imaging
Trial: 28457194
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg ICG administered up to 3 hours before imaging
Trial: 28457194
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg ICG administered up to 5 hours before imaging
Trial: 10498560
Drug: Penicillin G
RxNorm normalized name: penicillin G
DrugBank: Benzylpenicillin (DB01053)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin G benzathine
Trial: 2191993
Drug: L-648,051 (inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-648,051 (inhaled cysteinyl leukotriene antagonist)
Trial: 6782930
Drug: Lysine acetylsalicylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lysine acetylsalicylate (LAS) 125 mg/10 kg
Trial: 6782930
Drug: Lysine acetylsalicylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lysine acetylsalicylate (LAS) 250 mg/10 kg
Trial: 6782930
Drug: Oxycodone 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone 0.4 mg/10 kg
Trial: 6782930
Drug: Oxycodone 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone 0.8 mg/10 kg
Trial: 6782930
Drug: Lysine acetylsalicylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lysine acetylsalicylate (LAS) 250 mg/10 kg and Oxycodone 0.8 mg/10 kg
Trial: 31198138
Drug: High-flow nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow nasal cannula oxygen therapy (HFNC) with initial flow rate of 40 L/min
Trial: 28348504
Drug: Dexamethasone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (2 ml, 8 mg) with bupivacaine (18 ml, 0.5%)
Trial: 28348504
Drug: Control (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (2 ml normal saline with bupivacaine (18 ml, 0.5%))
Trial: 24642392
Drug: Biological antioxidant
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological antioxidant potential (BAP) levels measured at 6 months
Trial: 21502546
Drug: Androgen deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy (ADT) alone, consisting of goserelin and bicalutamide for 2 years
Trial: 15857212
Drug: D-002 40
RxNorm normalized name: D
DrugBank: Rosomidnar (DB17154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-002 40 mg/day
Trial: 15857212
Drug: D-002 100
RxNorm normalized name: D
DrugBank: Rosomidnar (DB17154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-002 100 mg/day
Trial: 10643535
Drug: Chemoendocrine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoendocrine therapy with mitozantrone and methotrexate (2M) +/‐ mitomycin‐C (3M) and tamoxifen, used concurrently with radiation
Trial: 27866873
Drug: Open-label tenofovir
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Open-label tenofovir (300 mg daily) for 1 year
Trial: 21917824
Drug: SC abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: SC abatacept (125 mg)
Trial: 21917824
Drug: SC abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: SC abatacept (125 mg) reintroduced after placebo
Trial: 19444379
Drug: Beverage containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beverage containing 200 mg calcium and 5 microg vitamin D daily for 30 days
Trial: 19444379
Drug: Beverage containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beverage containing 200 mg calcium daily for 30 days
Trial: 30477276
Drug: Lowest serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lowest serum 25(OH)D quartile (4.7–17.5 ng/mL)
Trial: 22197127
Drug: degarelix-ML group
RxNorm normalized name: Degarelix
DrugBank: Degarelix (DB06699)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: degarelix-ML group
Trial: 9935007
Drug: No antiarrhythmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antiarrhythmic medication (ICD-only group)
Trial: 7591508
Drug: Subjects with
RxNorm normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects with higher absorption and sustained attention
Trial: 2267970
Drug: Ivermectin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin (150 micrograms/kg) administered monthly for 12 months
Trial: 2267970
Drug: Ivermectin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin (150 micrograms/kg) administered monthly for 8 and 12 months
Trial: 2267970
Drug: Ivermectin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin (150 micrograms/kg) administered monthly
Trial: 6104874
Drug: Fixed betablocker
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed betablocker diuretic combination (Torrat, Boehringer Mannheim GmbH)
Trial: 31798894
Drug: Boot Camp
RxNorm normalized name: Booty Goo
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Boot Camp intervention (diabetes education and medication management via initial clinic and weekly virtual visits for 90 days)
Trial: 27590218
Drug: Edoxaban 60
RxNorm normalized name: edoxaban 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban 60 mg per day (reduced to 30 mg if certain factors present)
Trial: 24604308
Drug: Doxycycline 50
RxNorm normalized name: doxycycline 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 50 mg daily for 24 months
Trial: 22313516
Drug: Amantadine 50
RxNorm normalized name: amantadine 50 mg/5 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amantadine 50 or 100 mg
Trial: 21742102
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination of isosorbide dinitrate/hydralazine (FDC I/H)
Trial: 12374520
Drug: Glucosamine sulfate,
RxNorm normalized name: Glucosamine Sulfate, 500 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucosamine sulfate, 1500 mg once a day
Trial: 10815855
Drug: Excimer laser‐generated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Excimer laser‐generated 308‐nm UV‐B radiation (1 treatment at 8 and 16 MED multiples)
Trial: 8984537
Drug: Sequential empiric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential empiric therapy including amikacin and amphotericin B
Trial: 29448265
Drug: Mini dental
RxNorm normalized name: oxymetazoline hydrochloride Nasal Solution [Iliadin Mini]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mini dental implants (MDI)
Trial: 29448265
Drug: Standard-size implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-size implants (SSI)
Trial: 24570078
Drug: Nicardipine continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine continuous infusion (0.5 µg/kg per min)
Trial: 20357309
Drug: Computerised cognitive-behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computerised cognitive-behavioural therapy (CCBT)
Trial: 18418966
Drug: Tongguan Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tongguan Capsule (TGC)
Trial: 18418966
Drug: Western routine
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western routine therapy with anti-thrombosis and anti-coagulant agents
Trial: 16186280
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg vitamin C and 100 IU vitamin E (group V)
Trial: 16186280
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of magnesium plus zinc, vitamins C plus E (group MV)
Trial: 16186280
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg Mg and 30 mg Zn (group M)
Trial: 12639462
Drug: CCM (cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCM (cell culture medium supplemented with insulin, thyroxin and growth hormone)
Trial: 11018196
Drug: Fluvastatin 40
RxNorm normalized name: fluvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 40 mg IR
Trial: 11018196
Drug: Fluvastatin 80
RxNorm normalized name: fluvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 80 mg ER
Trial: 11018196
Drug: Fluvastatin 160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 160 mg ER
Trial: 11018196
Drug: Fluvastatin ER
RxNorm normalized name: fluvastatin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin ER (all doses)
Trial: 8639252
Drug: CyA (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CyA (7 mg/kg per day) and prednisolone
Trial: 8639252
Drug: CyA (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CyA (7 mg/kg per day), prednisolone, and oral nifedipine
Trial: 8639252
Drug: CyA (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CyA (4 mg/kg per day), prednisolone, and azathioprine
Trial: 29719179
Drug: Verubecestat 12
RxNorm normalized name: Verubecestat
DrugBank: Verubecestat (DB12285)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verubecestat 12 mg per day
Trial: 29719179
Drug: Verubecestat 40
RxNorm normalized name: Verubecestat
DrugBank: Verubecestat (DB12285)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verubecestat 40 mg per day
Trial: 28620677
Drug: LEB +
RxNorm normalized name: Leuprolide acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEB + peloid therapy (5 days a week for 2 weeks)
Trial: 28620677
Drug: LEB treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEB treatment alone
Trial: 25124939
Drug: Oleogel‐S10 once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oleogel‐S10 once daily (n = 53)
Trial: 25124939
Drug: Oleogel‐S10 twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oleogel‐S10 twice daily (n = 51)
Trial: 25124939
Drug: Placebo once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily (n = 25)
Trial: 25124939
Drug: Placebo twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily (n = 28)
Trial: 17531632
Drug: Gabexate mesylate
RxNorm normalized name: mesylate
DrugBank: Gabexate (DB12831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabexate mesylate 500 mg administered within 1 hour before ERCP (group A, 203 patients)
Trial: 17531632
Drug: Gabexate mesylate
RxNorm normalized name: mesylate
DrugBank: Gabexate (DB12831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabexate mesylate 500 mg administered within 1 hour after ERCP (group B, 203 patients)
Trial: 17531632
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution (group C, 202 patients)
Trial: 10420072
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (dalteparin, Fragmin(R), 10,000 IU s.c. once daily)
Trial: 10420072
Drug: Coumarin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coumarin therapy
Trial: 28339668
Drug: MCV4 booster
RxNorm normalized name: meningococcal MCV4, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCV4 booster dose
Trial: 22882249
Drug: Insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin aspart (IAsp) 12 IU
Trial: 22882249
Drug: Insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin aspart (IAsp) 24 IU
Trial: 22882249
Drug: Insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin aspart (IAsp) (all doses)
Trial: 22882249
Drug: Regular human
RxNorm normalized name: insulin regular human recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular human insulin (RHI) 12 IU
Trial: 22882249
Drug: Regular human
RxNorm normalized name: insulin regular human recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular human insulin (RHI) 24 IU
Trial: 14706125
Drug: Megace OS
RxNorm normalized name: megestrol acetate Oral Tablet [Megace]
DrugBank: Megestrol acetate (DB00351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megace OS (400 mg daily for 63 days)
Trial: 11593128
Drug: Midazolam, fentanyl,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam, fentanyl, and alfentanil as supplemental agents
Trial: 7950196
Drug: Persantin and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Persantin and Aspirin
Trial: 25329142
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of triamcinolone
Trial: 25329142
Drug: Heated lidocaine/tetracaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heated lidocaine/tetracaine (Trilexis) patch
Trial: 9883300
Drug: Tri-Nasal Nasal
RxNorm normalized name: Tri-Nasal Nasal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tri-Nasal Nasal Spray 200 micrograms qd
Trial: 9883300
Drug: Tri-Nasal Nasal
RxNorm normalized name: Tri-Nasal Nasal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tri-Nasal Nasal Spray 400 micrograms qd
Trial: 2213395
Drug: 400 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/kg IVIG daily for 4 days
Trial: 2213395
Drug: 1 gm/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 gm/kg IVIG as a single dose
Trial: 28385543
Drug: Rosuvastatin (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin (single doses)
Trial: 28385543
Drug: Rosuvastatin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin with intravenous rifampin (inhibited condition)
Trial: 25281416
Drug: Laquinimod 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laquinimod 0.5 mg/day
Trial: 25281416
Drug: Laquinimod 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laquinimod 1.0 mg/day
Trial: 23448846
Drug: Pharmacological therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological therapy for hypertension
Trial: 23448846
Drug: Demographic factors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Demographic factors (male gender, living in a regional area) and clinical factors (history of antihypertensive therapy, increased plasma creatinine, lower pretreatment pulse pressure, in-study use of multiple BP-lowering drugs)
Trial: 15290658
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg (n = 5068)
Trial: 15290658
Drug: Esomeprazole 20
RxNorm normalized name: esomeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20 mg (n = 1243)
Trial: 15290658
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg (n = 3018)
Trial: 15290658
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg (n = 2616)
Trial: 12536732
Drug: Intraoperative application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative application of mitomycin C (MMC) 0.4 mg/ml for 1 minute